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Abstract : Intraventricular administration of brain-derived neurotrophic factor (BDNF) can induce striatal neuro-
genesis. Epidermal growth factor (EGF), by expanding the mitotic pool of neural stem/progenitor cells in the sub-
ventricular zone (SVZ) responsive to neuronal instruction by BDNF, can potentiate this process. The objective of
this study was to investigate the induction of striatal regeneration and consequent functional benefits after chronic
infusion of BDNF and EGF in a R6/2 transgenic mouse model of Huntington’s disease (HD). At 6 weeks of age, the
mice were randomly assigned to groups receiving a continuous 2-week infusion of one of the following treatments
into the ventricle: combination of BDNF and EGF (B/E), BDNF, EGF, or phosphate buffered saline (PBS). Two
weeks after treatment, the B/E-treated mice revealed a significant increase of new neurons co-stained with BrdU and
βIII-tubulin in the ventricular side of neostriata (VZ~300 µm), compared with PBS controls. The newly generated
cells were also expressed as migrating neuroblasts co-labeled with doublecortin or PSA-NCAM in the SVZ. The sur-
vival rates of the new neurons were in the range of 30~50% at 6 weeks after treatment. For behavioral assessments,
the B/E combination therapy group showed a significant delay in motor deterioration relative to PBS controls in both
constant and accelerating rotarod as well as locomotor activity test 6 weeks after treatment. However, administration
of BDNF alone did not exhibit significant delays in motor deterioration in most of behavioral assessments. Neither
did motor performance improve in R6/2 mice treated only with EGF. In conclusion, induction of striatal regeneration
by the intraventricular administration of BDNF and EGF delayed disease progression in HD. Therefore, this treat-
ment may offer a promising strategy for restoration of motor function in HD.
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1. Introduction
It has been reported that stem cells and progenitor cells are
present not only in the embryonic state but also in the
subventricular zone (SVZ) and hippocampus of the adult brain.1
Although the capacity of these cells themselves for repairing
damaged tissue is largely limited, adult neurogenesis may be
enhanced by brain-derived neurotrophic factor (BDNF),
epidermal growth factor (EGF), fibroblast growth factor (FGF),
insulin-like growth factor-1 (IGF-1), and other growth factors.2-5
Namely, the newly generated neurons can migrate from SVZ
cells towards the olfactory bulb, and the recruitment of neurons
into the striatum may be increased by administration of BDNF.6-
9
 The fact that stem/progenitor cells are present in the adult brain
and the production of new neurons occurs in specific sites
suggests the possibility for the treatment of incurable
neurological diseases in the future. Nevertheless, it has been
reported that the new neurons are not sufficient to exhibit
functional recovery, or that they could not survive for a long time
even in the presence of BDNF.10,11 Therefore, in this study, it was
attempted to maximally increase BDNF-responsive
subventricular stem/progenitor cells, and to accelerate the
induction of striatal neurogenesis by combined administration of
EGF to the ventricle.
The degenerative loss of medium spiny neurons in the striatum
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is the primary finding observed in Huntington’s disease (HD).12
HD is an autosomal dominant disease that expanded CAG
repeats cause the production of mutant huntingtin protein which
can be neurotoxic.13 Specifically, it is a neurodegenerative
disorder that striatal neurons are gradually lost, resulting in
involuntary movements such as chorea and the problem of motor
coordination.12 For the treatment of HD, administration of
creatine,14-16 cystamine,17,18 coenzyme Q10,19 pyruvate,20
lithium,21 minocycline22,23 and histone deacetylase inhibitors,24,25
and stem cell transplant26 have been attempted. However, an
effective treatment has been still not available. Nevertheless, the
theory that wild-type huntingtin plays a certain role in
corticostriatal transport of BDNF was recently proposed.27,28 The
BDNF also regulates neurogenesis in addition to promoting
neuroprotection.29 Thus, administration of exogenous BDNF or
other growth factors in combination may be a good therapeutic
approach to prevent the progression of HD.30 
The newly generated cells in SVZ can migrate into the affected
striatum and differentiate to medium spiny neurons in HD.31 In
response to the degeneration that occurs in the neostriatum in HD,
the SVZ increases production of progenitor cells that migrate
towards the site of the damage, where they can differentiate into
mature neurons.32 To enhance the process, among multiple
approaches to exogenous trophic factor delivery, experimental
studies have employed continuous infusion via an osmotic mini-
pump.33-35 As mentioned above, if intraventricular administration
of BDNF and/or EGF induces striatal neurogenesis, it is
considered that the newly generated neurons can delay the
symptoms of HD. Therefore, we investigated that BDNF and/or
EGF administered alone or in combination has a therapeutic effect
on the functional outcomes of HD. 
2. Materials and Methods
2.1 Animal
As a transgenic mouse model of HD, the R6/2 model
(B6CBA-Tg(HDexon1)62Gpb/1J) that approximately 145
copies of CAG repeats were inserted exon 1 of the human HD
gene was used. The breeding pairs of the R6/2 model were
purchased from the Jackson Laboratory (Bar Harbor, ME), and
the subjects were produced by breeding ovarian transplant
hemizygote females with B6CBAF1/J males. The animals
were maintained in a facility accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC) under the Animal Protection Regulation with the
12-hour light/dark cycle. 
2.2 Genotyping
The confirmation of HD was determined by polymerase chain
reaction (PCR) of tail-tip DNA. In other words, approximately 1-
2 mm tail tip of mice was cut at 4 weeks after birth, and DNA
extraction was performed in proteinase K mixture solution at
55oC overnight. PCR reactions were performed in the presence
of forward primer CCGCTCAGGTTCTGCTTTTA and reverse
primer GGCTGAGGA AGCTGAGGAG at 94oC for 3 minutes,
35 cycles × (94oC for 30 seconds, 58oC for 1 minute, and 72oC
for 1 minute), 72oC for 2 minutes, and 4oC afterward. R6/2
transgenic mice were confirmed by performing electrophoresis
on 1.2 % agarose gel and detecting 611 bp bands (Fig 1A). 
2.3 Experimental Design
For behavioral testing, at 6 weeks of age, 76 HD mice were
randomly assigned to receive a continuous 2-week intraventricular
Figure 1. Genotyping and experimental design. Huntington’s disease was confirmed by detecting 611 bp bands (A) At 6 weeks of
age, intraventricular administration of BDNF and/or EGF was performed as shown in the above schematic figure (B) Experimental
schedule was described from birth to 12 weeks of age (C) BrdU: 5-bromo-2-deoxyuridine, RR: rotarod, OFT: open-field test.
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infusion of one of the following four treatments: a combination
of BDNF and EGF (B/E), BDNF, EGF, or phosphate buffered
saline (PBS) (n = 19 each). BDNF and EGF were each infused at
a concentration of 1 µg/ml using an Alzet micro-osmotic pump
(model 1002; 0.25 µl/hr infusion rate, 100 µl volume; Durect).
The infusion cannula (Brain Infusion Kit 3) was inserted using
stereotaxic coordinates (AP -0.5 mm from Bregma; ML -0.7 mm
from Bregma; DV -2.0 mm from dura) to the lateral ventricle
(Fig 1B), and the osmotic pump connected to this was inserted
into the dorsal subcutaneous tissue. In the other set of
immunohistochemistry, 2 weeks after surgery, newborn neurons
were evaluated in the neostriatum of HD and WT subjects (n = 5/
group). The schematic timeline of this experiment from birth to
12 weeks of age is provided in Fig 1C.
2.4 Behavioral Assessment
All subjects were assessed at 6 weeks of age as pre-operative
evaluation. To evaluate motor coordination, rotarod test was
performed at one week interval from 6 weeks to 12 weeks of age
using a rotarod treadmill (Cat No. 47600, UGO Basile, VA,
Italy). The latency when animals fall from the rod was measured
at the constant speed of 12 rpm and at the accelerating speed from
4 rpm to 40 rpm for 5 min. In each trial, it was performed 3 times,
and their mean latency was analyzed. For open-field test,
locomotor activity was also assessed at 2-week intervals using a
41×41×33 cm activity cage (Cat No. 7420, UGO Basile, VA,
Italy). The activity was automatically measured by the number of
the beams a mouse crossed in the activity cage consisting of 2
pairs of arrays emitting and sensing 16 infrared beams.
2.5 Immunohistochemistry
Mice were given an intraperitoneal injection of 5-bromo-2-
deoxyuridine (BrdU; 50 mg/kg, Sigma-Aldrich) once per day
for 12 days, beginning 1 day after stereotaxic surgery. Two
weeks after chronic infusion, new neurons were evaluated in
the neostriatum of HD and WT mice (n = 5/group). Briefly, the
animals were sacrificed, given an intracardiac perfusion of 4%
paraformaldehyde, and the brain tissues were harvested. They
were frozen and cryosectioned at 16-µm intervals, and
immunostaining was performed on six sections over a range of
256 µm. Sections were stained with the cell proliferation
marker BrdU and the neuronal marker βIII-tubulin (1:400,
Covance, NJ), and the double-labeled cells of BrdU+/βIII-
tubulin+ were assessed by confocal imaging. The number of
newly generated neurons was evaluated at intervals of 300 µm
from the ventricular zone (VZ) to evaluate the distribution of
new neurons in the neostriatum. The area of the neostriatum
were obtained using the MetaMorph Imaging System
(Molecular Device, Sunnyvale, CA), converted to the volume
(area×16 µm), and quantified as the density (/mm3). They were
also immunostained with BrdU and doublecortin (DCx; 1:400,
Chemicon), or PSA-NCAM (1:400, Sigma-Aldrich) to identify
migrating neuroblasts. In addition, the survival rates of the
newly generated cells were evaluated at 6 weeks after infusion
in another cohort of HD and WT mice (n = 5/group).
2.6 Statistical Analysis
The effect of BDNF and/or EGF on the generation of new
neurons and the functional outcomes after the intraventricular
infusion was evaluated for each group. Namely, the numbers of
BrdU+ or BrdU+/βIII-tubulin+ cells (/mm3) in the neostriatum
were analyzed as a function of distribution from the VZ by one-
way ANOVA followed by post hoc Bonferroni comparison
using SPSS. In addition, the findings of the delay in functional
deterioration by striatal regeneration or neuroprotective effect
of BDNF itself were examined. P < 0.05 was considered to be
statistically significant.
3. Results
3.1 Rotarod Performance
The mice consist of the four groups as a function of
administrating the BDNF and/or EGF at 6 weeks of age; B/E,
BDNF, EGF, and PBS. The rotarod performance prior to surgery
of each group was not significantly different. However, when
the rotarod test was performed weekly, the B/E combination
therapy group started to show a significant delay in motor
deterioration in comparison with the PBS group 6 weeks after
surgery (12 weeks of age) at both 1 min constant rorarod (Fig 2a)
and at 5 min constant rotarod (Fig 2B) (p < 0.05 by one-way
ANOVA with posthoc Bonferroni test). The mice treated with
BDNF alone also showed a significantly longer latency at 12
weeks of age, compared with the PBS group at 1 min constant
rotarod (p < 0.05) (Fig 2A). At the accelerating rotarod,
significant treatment effects were shown in the B/E combination
therapy group in comparison with the EGF group post-treatment
6 weeks (12 weeks of age) as well as the PBS group post-
treatment 5-6 weeks (11-12 weeks of age) (p < 0.05) (Fig 2C). 
3.2 Locomotor Activity
When open-field locomotor activity was evaluated for 10
min or 60 min, the activity of each group was not significantly
different before treatment. In addition, when evaluation was
limited to the initial 10 min, statistical differences were not
shown among the R6/2 HD subjects, although the B/E-treated
mice exhibited a higher tendency of beam crossing incidences
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6 weeks after surgery (12 weeks of age) (Fig 3A). However, in
the locomotor activity test for total 60 min, the B/E
combination therapy group showed a significant delay in
activity deterioration in comparison with the PBS controls at 12
weeks of age (p < 0.05 by one-way ANOVA with posthoc
Bonferroni test) (Fig 3B). 
3.3 Immunohistochemistry
The ability of BDNF combined with EGF to induce
striatal neurogenesis from endogenous neural stem cells in
the SVZ was assessed immunohistologically by counting the
number of newly generated neurons co-labeled with BrdU
and βIII-tubulin in WT and HD mice after 2 weeks of
chronic infusion (Fig 4A,B). As described previously,24 EGF
could potentiate striatal neurogenesis by expanding the
mitotic pool of SVZ cells responsive to neuronal instruction
by BDNF. In addition, we found that the newly generated
cells were expressed as migrating neuroblasts labeled with
DCx or PSA-NCAM in the SVZ and the ventricular side of
neostriatum (Fig 4C,D). When the new neurons were
evaluated at 6 weeks after infusion, their survival rates were
in the range of 30~50%, suggesting that more than a half of
the newly generated neurons might be prone to die (Table 1).
Particularly, both WT and R6/2 transgenic HD mice treated
with B/E showed a significant induction of striatal
neurogenesis in the ventricular side of neostriatum
(VZ~300 µm) compared with PBS controls (p < 0.05 by
one-way ANOVA with posthoc Bonferroni test) (Fig 4E). In
other words, approximately 50~80% of the new neurons
were distributed in the area within 300 µm from VZ (Table
2). However, striatal neurogenesis did not show a statistical
difference among the groups in the other area of neostriatum
Figure 2. Rotarod performance. At 1-min constant rotarod (A), the B/E and BDNF group significantly delayed motor deterioration
compared with PBS controls post-treatment 6 weeks (12 weeks of age). At 5-min constant rotarod (B), mean rotarod latency was
significantly sustained post-treatment 6 weeks after intraventricular infusion of BDNF and EGF. At accelerating rotarod (C), the B/
E-treated mice showed a significant delay in motor deterioration 5-6 weeks after treatment. *p < 0.05 compared with PBS controls.
**p < 0.05 compared with EGF and PBS group. B/E: combination of BDNF and EGF, BDNF: brain-derived neurotrophic factor, EGF:
epidermal growth factor, PBS: phosphate-buffered saline.
Figure 3. Open field activity test in the 10-min locomotor activity
test (A), statistical differences were not shown among the
subjects. in the 60-min locomotor activity test (B), the B/E
combination therapy group significantly delayed activity
deterioration compared with PBS controls post-treatment 6 weeks
(12 weeks of age). *p < 0.05 compared with PBS controls. B/E:
combination of BDNF and EGF, BDNF: brain-derived
neurotrophic factor, EGF: epidermal growth factor, PBS:
phosphate-buffered saline.
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Figure 4. Induction of striatal neurogenesis. HD mice treated with B/E (A) showed more striatal recruitment of new neurons stained
with BrdU+/βIII-tubulin+ than PBS controls (B). The newly generated neurons were expressed as migrating neuroblasts labeled with
DCx+ (C) or PSA-NCAM+ (D) in the SVZ. Both WT and R6/2 transgenic mice treated with B/E exhibited a significant induction
of striatal neurogenesis in the ventricular side of neostriatum (VZ~300 µm) compared with PBS controls (E). *p < 0.05 compared with
PBS controls. BrdU: 5-bromo-2-deoxyuridine, DCx: doublecortin, B/E: combination of BDNF and EGF, BDNF: brain-derived
neurotrophic factor, PBS: phosphate-buffered saline. Scale bars: 20 µm (C, D).
Table 1. Newly generated striatal neurons and survival rates as a function of disease and treatment
Treatment 2 weeks after infusion 6 weeks after infusion Survival rate
Volume (×10-3mm3)
WT mice B/E 50.7±0.7 46.6±4.1 -
BDNF 53.8±1.8 51.1±2.6 -
PBS 49.6±1.3 52.2±2.4 -
HD mice B/E 42.5±1.9 36.2±2.0 -
BDNF 47.0±4.6 38.5±2.4 -
PBS 44.3±3.9 33.9±5.7 -
BrdU+ cells/mm3
WT mice B/E  2062±148*  1581±114* 75.9%
BDNF 1571±229  1097±116* 69.8%
PBS  965±126 497±82 51.3%
HD mice B/E  2184±197*  1909±271* 78.3%
BDNF 1735±69 1350±52* 77.3%
PBS 1389±47 770±89 55.4%
BrdU+/βIII-tubulin+cells/mm3
WT mice B/E  211±40*  90±23* 42.3%
BDNF 114±25 44±8 38.1%
PBS  25±10  7±5 30.1%
HD mice B/E  260±64*  123±24* 49.9%
BDNF 156±14  63±11 40.7%
PBS 43±8 14±6 33.7%
Values are mean±S.E. *p < 0.05 compared with PBS controls.
VZ: ventricular zone, WT: wild-type, HD: Huntington’s disease, B/E: combination of BDNF and EGF, BDNF: brain-derived neurotrophic
factor, PBS: phosphate-buffered saline, BrdU: 5-bromo-2-deoxyuridine
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(300~1200 µm) (Fig 4E, Table 2). 
4. Discussion
Recently, experimental studies engaging various neurotrophic
factors alone or in combination with stem cell therapy or
induced pluripotent stem cell technology have been actively
investigated for various diseases.26,36,37 Nonetheless, its
treatment effectiveness on HD is not yet clear, and the
standardized methods for the evaluation are not available.
Particularly, a consensus on partial effects has not been reached.
In our study, after the intraventricular administration of BDNF
and/or EGF, functional effects derived from striatal
neurogenesis, in other words, the delay of motor deterioration
with time, were assessed by the evaluation of rotarod and
locomotor activity. For this, as an animal model of HD, R6/2
transgenic mice prepared to contain approximately 145 CAG
repeats in the first exon of human HD gene were used.38,39 The
R6/2 model has been widely investigated, and their
neuropathological findings as well as clinical symptoms are
similar to juvenile HD patients. They usually began to show the
degeneration of motor function at 6 weeks after birth. From 8-9
weeks of age, they exhibit involuntary motor symptoms such as
tremor as well as chorea, and overt behavior symptoms such as
gait disturbance. From approximately 12-13 weeks of age,
severe reduction of the locomotor activity is shown, and
afterward, they die in most cases.40,41 Therefore, the mice were
treated with BDNF and/or EGF at 6 weeks of age when the
animals began to exhibit behavioral dysfunction, and sacrificed
at 12 weeks of age before death.
Our study demonstrated that intraventricular administration
of BDNF and EGF could delay the motor deterioration 6 weeks
after treatment. The histological results also showed that
combination therapy significantly induced striatal neurogenesis
after 2 weeks of chronic infusion. In particular, the new neurons
were significantly recruited into the ventricular side of
neostriatum, suggesting that striatal regeneration might be
derived from neural stem/progenitor cells in the SVZ.
Moreover, the newly generated cells, expressed as migrating
neuroblasts immunostained with DCx or PSA-NCAM in the
Table 2. Distribution of newly generated striatal neurons according to the distance from ventricular zone
From VZ ~ 300 µm 300~600 µm 600~900 µm 900~1200 µm
Volume (×10-3mm3)
WT mice B/E 12.5±0.4 (24.7%) 13.0±0.3 (25.5%) 12.6±0.4 (24.8%) 12.7±0.3 (25.0%)
BDNF 13.8±1.0 (25.6%) 13.4±1.0 (24.9%) 12.8±0.3 (23.8%) 13.9±1.0 (25.8%)
PBS 11.6±0.4 (23.3%) 12.7±0.5 (25.5%) 12.5±0.8 (25.1%) 12.9±0.2 (26.1%)
HD mice B/E 10.0±0.8 (23.5%) 10.3±0.5 (24.3%) 11.2±0.5 (26.3%) 11.0±0.9 (26.0%)
BDNF 11.9±1.1 (25.4%) 12.4±1.2 (26.4%) 10.4±0.9 (22.2%) 12.2±1.2 (26.0%)
PBS 11.0±0.8 (24.8%) 11.0±0.6 (24.7%) 11.3±0.7 (25.5%) 11.0±1.5 (24.9%)
BrdU+ cells/mm3
WT mice B/E 4579±640* (54.8%) 1633±308 (19.5%) 1185±264 (14.2%) 966±255 (11.6%)
BDNF 3697±389 (59.4%)  996±304 (16.0%) 851±219 (13.7%)  680±198 (10.9%)
PBS 2537±479 (63.1%) 637±72 (15.9%) 506±112 (12.6%) 339±43 (8.4%)
HD mice B/E 4786±330* (55.6%) 1714±140 (19.9%) 1143±212 (13.3%) 969±68 (11.3%)
BDNF 4263±365 (61.8%) 1239±302 (17.9%) 713±115 (10.3%) 687±137 (10.0%)
PBS 3403±103 (60.9%) 972±110 (17.4%) 577±107 (10.3%) 631±102 (11.3%)
BrdU+/βIII-tubulin+cells/mm3
WT mice B/E 598±114* (69.7%) 150±39 (17.5%) 64±28 (7.4%) 46±19 (5.4%)
BDNF 343±42 (75.7%) 63±39 (13.9%) 31±31 (6.8%) 16±16 (3.6%)
PBS 55±22 (53.7%) 18±18 (17.6%) 29±18 (28.7%) 0±0 (0%)
HD mice B/E 663±124* (68.4%) 155±23 (15.9%) 123±21 (12.7%) 29±29 (3.0%)
BDNF 432±36 (70.2%) 108±33 (17.5%) 62±43 (10.0%) 14±14 (2.3%)
PBS 92±5 (54.2%) 52±21 (30.4%) 14±14 (8.4%) 12±12 (7.0%)
Values are mean±S.E. *p<0.05 compared with PBS controls.
VZ: ventricular zone, WT: wild-type, HD: Huntington’s disease, B/E: combination of BDNF and EGF, BDNF: brain-derived neurotrophic
factor, PBS: phosphate-buffered saline, BrdU: 5-bromo-2-deoxyuridine
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SVZ, migrated and differentiated to striatal neurons with proof
of neuronal marker βIII-tubulin. 
Administration of BDNF and EGF promoted functional
benefits consistently in various motor functions. However,
mice treated with BDNF alone did not show any statistical
increment in 5 min constant rotarod, accelerating rotarod, and
locomotor activity test, although they exhibited an improved
rotarod latency only in the 1 min constant rotarod test. In other
words, the finding that significant differences of rotarod latency
and locomotor activity in the B/E group were shown compared
with PBS controls and the finding that administration of BDNF
alone did not show a significant delay in motor deterioration in
most of the behavioral assessments could be considered as a
treatment effect mediated by newly generated neurons induced
by combination therapy rather than the neuroprotective effect
of BDNF itself. Furthermore, any behavioral performance in
the mice treated with EGF alone was not different from that in
PBS controls. Rather than a direct benefit, EGF seems to
expand the mitotic pool of SVZ cells responsive to neuronal
instruction by BDNF, and thereafter to potentiate striatal
neurogenesis and functional benefits.9 
In this study, the rotarod tests were performed with various
methods to evaluate motor coordination and balance sensitively
and reliably.8,42 Namely, both constant speed and accelerating
speed method were used, and the mean latency of the constant
rotarod was analyzed by terminating at 1 min or 5 min. In
addition, general locomotor activity was investigated by
dividing the evaluation time to 10 min or 60 min. In such
manners, the most sensitive and reliable evaluation methods
were assessed by varying the test time. As a result, the 1 min
constant rotarod test detected the differences between the mice
treated with BDNF alone and PBS controls, whereas the BDNF
group did not exhibit a significant delay of motor deterioration
in 5 min constant and accelerating rotarod tests. Based on the
observation that constant rotarod performance was terminated
as a maximal latency of 1 min, it suggests that 1 min rotarod test
might detect partial neuroprotective effect of BDNF more
sensitively. Therefore, it was found that appropriate evaluation
duration should be required to compare treatment groups
showing partial effects. Considering our results, it is thought that
appropriate test methods should be selected depending on the
subject groups to be compared. Similarly, when locomotor
activity was evaluated by dividing the test results to 10 min and
60 min in a R6/2 HD mouse model, the difference between B/E
combination therapy group and PBS controls was shown only in
the 60 min locomotor activity test. Thus, it is thought that
previous result of the evaluation for 10 min activity may not be
sufficient to obtain reliability.26
We confirmed that administration of BDNF and EGF
induced striatal neurogenesis and migration from SVZ cells
into the neostriatum in HD. The striatal regeneration could
exert treatment effects of delaying motor deterioration and
disease progression, implying a causal association of functional
outcomes with histological results. In other words, the
functional outcomes may be derived from the induction of
striatal neurogenesis rather than from the neuroprotective
effects of BDNF itself in HD. This result is consistent with our
previous study in an animal model of hypoxic-ischemic brain
injury.9 It is also considered that various behavioral assessments
should be performed by appropriate methods to evaluate
treatment effects more sensitively and reliably. 
As a limitation of this study, R6/2 transgenic mice may not be
a sufficient animal model of HD to evaluate striatal regenera-
tion and functional effects of our treatment. It thus is thought if
N171-82Q or YAC transgenic mouse model with neurological
symptoms similar to HD patients were used, the direct link
between motor function and histological outcome could be
determined simultaneously at the appropriate time. In addition,
we could not define the role of the newly generated cells,
because this study did not show functional synapses and neural
pathway regenerated from the survived new neurons. Through
the further studies, we should be able to elucidate  the rapeutic
mechanism of functional improvement such as synaptic
formation and the connection of striatopallidal pathway.
5. Conclusion
The induction of striatal regeneration by intraventricular
administration of BDNF and EGF for 2 weeks delayed motor
deterioration and disease progression in HD. Therefore, this
treatment may offer a promising strategy for the restoration of
motor function in incurable neurodegenerative diseases such as
HD.
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